Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

Kip KE, Swoger JM, Grandinetti LM, Barrie AM 3rd, Greer JB, Regueiro MD.

Inflamm Bowel Dis. 2013 May;19(6):1164-72. doi: 10.1097/MIB.0b013e31828075bd.

PMID:
23518804
2.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
3.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
4.

Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.

Smith LS, Nelson M, Dolder CR.

Ann Pharmacother. 2010 Feb;44(2):333-42. doi: 10.1345/aph.1M314. Epub 2010 Jan 5. Review.

PMID:
20118143
5.

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Epub 2011 Sep 29. Review.

6.

The safety of biologic agents in the treatment of inflammatory bowel disease.

Shepela C.

Minn Med. 2008 Jun;91(6):42-5. Review.

PMID:
18616021
7.

Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.

Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8. Review.

PMID:
25105206
8.
9.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
10.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
11.

Adverse cutaneous reactions induced by TNF-alpha antagonist therapy.

Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E.

South Med J. 2009 Nov;102(11):1133-40. doi: 10.1097/SMJ.0b013e3181bb554c. Review.

PMID:
19864977
12.

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

Gisbert JP, Marín AC, McNicholl AG, Chaparro M.

Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4. Review.

13.

Safety considerations when using anti-TNFα therapy to treat Crohn's disease.

Pagnini C, Arseneau KO, Cominelli F.

Expert Opin Drug Saf. 2015 Jan;14(1):31-44. doi: 10.1517/14740338.2015.976610. Epub 2014 Nov 15. Review.

PMID:
25400161
14.

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

Peyrin-Biroulet L.

Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43. Review.

PMID:
20485259
15.
16.

Optimizing anti-TNF treatment in inflammatory bowel disease.

Rutgeerts P, Van Assche G, Vermeire S.

Gastroenterology. 2004 May;126(6):1593-610. Review.

PMID:
15168370
17.

Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.

Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L.

J Crohns Colitis. 2013 Nov;7(10):769-79. doi: 10.1016/j.crohns.2013.01.009. Epub 2013 Mar 1. Review.

18.

[Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].

Schreiber S.

Dtsch Med Wochenschr. 2007 Aug;132(34-35):1770-4. Review. German.

PMID:
17713889
19.

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.

Williams CJ, Peyrin-Biroulet L, Ford AC.

Aliment Pharmacol Ther. 2014 Mar;39(5):447-58. doi: 10.1111/apt.12624. Epub 2014 Jan 20. Review.

20.

Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.

Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G.

Eur J Gastroenterol Hepatol. 2010 Jul;22(7):779-86. doi: 10.1097/MEG.0b013e328331b654. Review.

PMID:
19786877

Supplemental Content

Support Center